Reuters has the wire-story, this afternoon:
. . . .The synthetic hormone Livial, designed as an alternative to hormone replacement therapy, makes it significantly more likely a woman's breast cancer will come back, Dutch researchers said on Tuesday.
Breast cancer was 40 percent more likely to come back in woman taking Schering Plough Corp's (SGP.N) Livial, a finding so pronounced the researchers said they stopped the trial six months early.
About 70 percent of the recurrent tumours killed the patients. . . .
This effect has been known for a while -- and will be likely only if MDs prescribe Livial "off-label" -- but apparently that had been more common than was originally thought.
Sad.
No comments:
Post a Comment